Kulkarni SG, Pegram AA and Smith PC Disposition of Acetaminophen and Indocyanine Green in Cystic Fibrosis-Knockout Mice AAPS PharmSci 2000;
2
(2)
article 18
(https://www.pharmsci.org/scientificjournals/pharmsci/journal/18.html).
Disposition of Acetaminophen and Indocyanine Green in Cystic Fibrosis-Knockout Mice
Submitted: March 15, 2000; Accepted: June 7, 2000; Published: June 22, 2000
Swarupa G. Kulkarni1, Anita A. Pegram2 and Philip C. Smith1
1Division of Drug Delivery and Disposition, School of Pharmacy, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599
2Wake Forest University Medical Center, Winston Salem, NC 27157
Correspondence to: Philip C. Smith Telephone: (919) 962-0095 Facsimile: (919) 966-0197 E-mail: pcs@email.unc.edu
|
Keywords: Acetaminophen Altered Pharmacokinetics Clearance cftrm1UNC-Knockout Mice Cystic Fibrosis Indocyanine Green (ICG)
|
Abstract
Drug treatment poses a therapeutic challenge in cystic
fibrosis (CF) because the disposition of a number of drugs is altered in CF.
Enhanced clearance of acetaminophen (APAP) and indocyanine green (ICG) have
previously been reported in CF patients. The objective of the current study was
to investigate if the CF-knockout mouse model (cftrm1UNC ) shows altered pharmacokinetics similar to those seen in CF patients using the 2 model
compounds APAP and ICG. Clearance (CL/F) of APAP and renal (CLR ) and
formation (CLf ) clearance of acetaminophen glucuronide (AG) and acetaminophen sulfate (AS) were determined in CF-knockout mice following
administration of APAP (50 mg/kg, intraperitoneal). CLR of AS was 19.5 and 12.9 (mL/min per kg) and CLf of AS was 10.4 and 6.7 mL/min per kg for homozygous and heterozygous males, respectively, which was
significantly different between groups. CLR of AG was 6.3 and 4.8 mL/min per kg and CLf of AG was 9.6 and 8.9 mL/min per kg for homozygous and heterozygous males, respectively, although not reaching
statistical significance. No significant differences were noted in either
ClR or CLf of AG and AS in female CF mice. Plasma
concentrations of ICG (10 mg/kg, intravenous) were determined over 0 to 15
minutes. Homozygous females showed a higher apparent volume of distribution (96
mL/kg) relative to heterozygous females (72 mL/kg). Similar to CF patients, a
trend toward a lower Cmax was noted in homozygous male and female mice. However, contrary to human data, no significant differences in CL of ICG
were noted. These results suggest that the CF-knockout mice have potential as a
model for studying altered drug disposition in CF patients.
Introduction
Cystic fibrosis (CF) is the most common fatal genetic disease
in the Western world. In the United States, approximately 30,000 people are
living with the disease, and there are 1,000 new cases diagnosed each year.
About 5% of Caucasians are asymptomatic carriers, and 1 child in approximately
2,500 of European descent carries 2 defective copies of the gene and has the
disease1. In general, altered pharmacokinetics of numerous drugs in the CF population include increased volume of distribution (Vd), decreased plasma
concentrations, and enhanced renal and non-renal clearance of drugs.
The mechanistic basis for the altered pharmacokinetics in CF
is unknown, although alterations in hepatic metabolism, blood flow, or transport
have been suggested2-4. Determining a mechanism for altered pharmacokinetics
of drugs in CF is unlikely if experimentation is limited to clinical studies.
The use of an appropriate animal model to study this phenomenon is highly
desirable because it would permit more invasive investigations and provide the
ability to perform biochemical studies with isolated tissues.
In the present study, we test the hypothesis that the
CF-knockout mouse can be used as an animal model to predict the altered
pharmacokinetics of drugs in CF. Increased clearance of acetaminophen (APAP) and
indocyanine green (ICG) has been reported in CF patients2-5. In order to test
the above hypothesis, pharmacokinetics of 2 model compounds, APAP and ICG, were
studied in CF-mice. Results from the study indicate that CF-knockout mice appear
promising for studying the altered pharmacokinetics in CF.
Materials and Methods
Animals
Cftrm1UNC -knockout mice generated at the University of North Carolina-Chapel Hill animal facility were used in this study
and are a hybrid strain containing genetic material from C57BL/6, 129/SvEv,
Balb/c, and DBA/2 mice6. Cftrm1UNC -knockout mice breed and pass on the defective cftr gene in a simple Mendelian pattern7. Cftrm1UNC -knockout mice are maintained on Colyte (PEG 3350 and electrolytes) to prevent intestinal obstructions, resulting in soft stools
without diarrhea6.
Genotyping the cftrmiUNC-knockout mice
Tail DNA from the CF-mice was isolated and stored at 2 to
8°C in Tris-EDTA using the protocol of Miller et al, 19888. Mice were
then genotyped by polymerase chain reaction (PCR) (Robocycler; Stratagene, La
Jolla, CA) using a protocol provided by the Cystic Fibrosis Center, University
of North Carolina-Chapel Hill. Primers used were 67 Common primer (CAG TGA AGC
TGA GAC TGT GAG CTT), 3215+ (CTG TAG TTG GCA AGC TTT GAC), and 45- (ACA CTG CTC
GAG GGC TAG CCT CTT C). Products of the PCR were run on a 1% agarose gel,
followed by staining with ethidium bromide, and were viewed on an ultraviolet
transilluminator.
Materials
APAP, acetaminophen glucuronide (AG), 3-acetamidophenol, and
ICG were purchased from Sigma Chemical (St. Louis, MO). Acetaminophen sulfate
(AS) was generously provided by Dr. Marilyn Morris (State University of New York
at Buffalo, Buffalo, NY).
Animal Treatment
For studies with APAP, adult mice (cftrm1UNC ) were
housed individually in metabolism cages with free access to food and water. Each
mouse was administered 50 mg/kg of APAP as a 10 mg/mL solution. Urine was
collected over 18 hours, then centrifuged to remove solid contaminants. The
volume of the supernatant was measured then frozen at -20°C. After a washout period of 7 days, the same mice were injected with APAP (50 mg/kg, intraperitoneal [ip]), and blood samples were collected sequentially by tail
artery bleeding at 0, 15, 30, 45, 60, 120, and 180 minutes in males and 0, 5,
10, 15, 20, 25, 30, 45, 60, 120, and 180 minutes in females. The samples were
then centrifuged, and plasma was frozen at -20°C until
high-performance liquid chromatography (HPLC) analysis. For studies with ICG,
mice were injected with ICG (10 mg/kg, intravenous [iv]) via the tail vein as a
2 mg/mL solution. The solution was made daily and protected from light to
minimize degradation. Blood was collected at 2, 4, 6, 8, 10, and 15 minutes,
centrifuged, and the plasma frozen at -20°C prior to assay.
Drug and Metabolite Analysis
The procedure used for the assay of APAP and its 2 major
metabolites was similar to that described previously9. Briefly, a
reversed-phase HPLC assay was used for the detection of APAP and its
metabolites. The mobile phase was 7% acetonitrile 50 mM sodium sulfate and 50
mM potasssium phosphate buffer with a flow rate of 1.3 mL/min. APAP, AG, and AS
were detected at 254 nm. Retention times were approximately 4.5, 6, 8, and 12
minutes, respectively, for AG, AS, and APAP and the internal standard
(3-acetamidophenol). For HPLC assay of ICG, the procedure used was similar to
that described previously10,11. Briefly, chromatography was performed on a
reversed-phase column (Bondapack C18; Water's Associates, Milford, MA) employing
a mobile phase of 50 mM phosphate buffer (50 mM
KH2 PO4 :K2 HPO4 ; pH =
5.52):acetonitrile (55:45), with a flow of 2 mL/min. ICG was detected at 720 nm
and had a retention time of approximately 5.5 minutes.
Free fraction of APAP and its metabolites AG and AS were
determined by ultrafiltration (Amicon, Bedford, MA). Plasma from CF mice was
spiked with APAP, AG, or AS and transferred to the sample reservoir of the
filtration device and centrifuged at 900 g for 10 minutes at ambient
temperature. Total and free concentrations of APAP, AG, and AS were determined
by HPLC.
Pharmacokinetic and Statistical Analysis
Pharmacokinetic analysis was performed using noncompartmental
analysis with WinNonlin (Pharsight, Mountain View, CA). Assuming F = 1 for ip
APAP, clearance (CL/F) of APAP, renal clearance (CLR ), and formation clearance (CLf ) of acetaminophen glucuronide (AG) and acetaminophen sulfate (AS) were determined. Formation clearances of AS and AG were calculated
based on assumptions similar to those employed by the human study; that is, no
sequential or renal metabolism occurred, and all metabolite formed was recovered
in the urine. Because the disposition profile of ICG was best described by a
1-compartment model, pharmacokinetic parameters (CL, Cmax , k, and V) were determined by this approach. Pharmacokinetic data are expressed as mean
± SD. Comparison between values was made using a general linear models
(glm) followed by least square means analysis. Data were analyzed using
Statistical Analysis System (SAS Institute, Cary, NC). The acceptable level of
statistical significance was P ≤ .05.
Results
APAP Pharmacokinetics in the CF Mouse
Pharmacokinetic parameters of APAP (50 mg/kg, ip) determined
in male and female CF mice are shown in Tables 1 and 2. A representative plasma profile of APAP
and its metabolites AG and AS in a male CF mouse is represented in Figure 1. Similar to CF patients, significant differences
in renal clearance (CLR,AS ) and clearance of formation
(CLf,AS ) of AS were noted between heterozygous and homozygous CF male
mice. However, no significant differences in either total systemic clearance
(CL/F, assuming F = 1), renal clearance (CLR,AG ), or formation
clearance (CLf,AG ) were noted between the homozygous and heterozygous
CF mice (Tables 1 and
2 ). Homozygous male mice did show a trend towards increased renal clearance (CLR,AG ) and an increased clearance of formation (CLf,AG ) of AG compared to the heterozygous males (controls) (Table 1 ), although statistical significance was not obtained in this case. Although a trend toward increased
clearance was seen in homozygous females, these females did not differ
significantly from the heterozygous females in either CLR or
CLf for AG and AS (Table 2 ). Significant differences were noted between male and female CF mice in total clearance (CL/F) and renal clearance of AS (CLR,AS ) (Tables 1 and 2 ), which was not
unexpected in an inbred strain of mice. Sex-selective expression of different
enzymes has already been reported in mice12,13. Sex differences in APAP sulfation and glucuronidation have been reported in Sprague Dawley rat
hepatocytes where increased sulfation of APAP is reported in male rats14. Such sex-specific differences have been reported for other substrates besides APAP like HMBA (7-hydroxymethyl-12-methyl-benz[a] anthracene). Adult female rat
livers showed a much higher cytosolic sulfotransferase activity for HMBA
metabolism compared to male rats15. Sex differences have also been reported in glucuronide metabolism of pirmenol (an anti-arrhythmic drug developed by
Warner Lambert/Parke Davis)16. Other enzymes besides Phase II metabolic enzymes also show such sex-specific differences12,17. Differences in transporter expression have also been recently reported18,19. Although not
much information regarding sex-specific expression of phenolsulfotransferase
(PST), UDP-glucuronyl transferases (UGT), or transporter expression in humans or
the cftrm1UNC -knockout mice is currently available in literature, it is likely that the sex-specific differences noted for APAP are attributable to
differences in expression of specific enzymes involved in metabolism or
transport of APAP metabolites. Urinary recovery of APAP was similar to that
reported in humans where about 65% to 75% of APAP is excreted as the metabolites
AG and AS, (Tables 1 and
2 )5. Free fraction (fu ) of APAP and its metabolites AG and AS in plasma were not measurably different in the small
number of samples analyzed (Tables 1 and
2 ).
ICG Pharmacokinetics in the CF Mouse
Following administration of 10 mg/kg ICG, pharmacokinetic
parameters were determined (Table 3 ) with a
representative plasma profile (Figure 2 ). The
disposition profile for ICG was best described by a 1-compartment model. This is
similar to the human situation in which a 1-compartmental fit for ICG has been
reported in CF patients3,4. CF-knockout mice did not show any difference in total systemic clearance (CL), unlike the situation in CF patients, wherein
increased clearance was reported to correlate with the severity of CF2.
Similar to the results with APAP, gender differences in clearance of ICG were
noted in CF mice. Homozygous female CF-mice showed an increased V when compared
with the heterozygous mice used as controls (Table 3 ). These results are in agreement with previous reports of an increase in
V for ICG in CF patients3,4. Similar to CF patients, homozygous CF-mice also showed a trend towards lower peak concentrations of ICG relative to heterozygous
mice (Table 3 ). Blood-to-plasma ratios for ICG were 0.58 ± 0.18 in (-/-) female mice vs. 0.55 ± 0.025 in (+/-) female mice.
Discussion
Studies in CF patients have revealed altered pharmacokinetics
for diverse drugs such as gentamicin, tobramycin, dicloxacillin, cloxacillin,
theophylline, cyclosporin, APAP, lorazepam, and ICG3. Alterations in pharmacokinetics include lower plasma concentrations, increased total plasma
clearance, and an increase in apparent steady-state volume of distribution.
Mechanisms that account for and adequately describe these alterations in CF have
not been determined.
Elucidating a mechanism for altered absorption and clearance
of drugs is unlikely if experimentation is limited to CF patients. A predictive
animal model to study altered drug disposition in CF is therefore desirable. The
objective of this study was to evaluate the cftrm1UNC mouse7 as a
potential animal model to predict alterations in pharmacokinetics observed in CF
patients, so that compounds that have altered disposition may be identified, and
thus drug therapy may be optimized more rationally. This mouse model has altered
gastrointestinal and hepatobiliary abnormalities similar to that seen in CF
patients20 but has not previously been evaluated as a model for drug disposition in CF.
Preliminary studies were conducted using 2 model compounds,
APAP and ICG, in CF-knockout mice using heterozygous (+/-) littermates as
controls. Increased clearance of both APAP and ICG has been reported in CF
patients2,5. Increased clearance of APAP in CF patients has been attributed to greater metabolic clearance of APAP to AG and AS5. CL/F was found to be 1.5-fold different between CF patients and controls (0.36 vs. 0.25 L/min per kg, respectively) with a 1.7-fold higher CLf of the glucuronide and sulfate. A trend toward a correlation between the NIH score (index of severity
of the disease) and CLf, AG and CLf, AS was also found in
CF patients5.
These preliminary experiments with APAP in CF mice revealed
results similar to those seen in humans; ie, a trend of increased CLf,AG and CLf,AS , although for the sample size employed, only
CLf,AS was significantly different (Tables 1 and 2 ). Conversion of
APAP to its major metabolites via the liver involves 3 distinct steps, uptake,
metabolism, and efflux, and alterations in any of these could be responsible for
the observed increased clearance.
APAP is a moderately water- and lipid-soluble weak organic
acid with a pKa of 9.5, and is largely uncharged at physiological pH. It is
reasonable to assume that APAP should be able to cross the cell membrane by
simple diffusion alone. However, the presence of a carrier-mediated system that
may contribute to uptake at concentrations encountered in vivo has been reported21. Two metabolic inhibitors, 2,4-dinitrophenol and iodoacetate, reduced the
uptake of APAP into hepatocytes, suggesting that uptake of acetaminophen is a
combination of a saturable active process and simple diffusion22.
Conjugation of the drug within the cell is the second step.
Because the glucuronidation of APAP at the dose used in the study is unlikely to
be rate-limited by the availability of the cofactor UDP glucuronic acid23,24 ,
increased glucuronidation of APAP in the CF-knockout mice may be attributable to
an induction or activation of UGT. Preliminary in vitro studies of APAP
glucuronidation using mouse liver microsomes suggest no apparent difference in
either Vm or Km for metabolism of APAP by UGT. Increased formation of AS could
either arise from an increased hepatic PST activity or from an increase in
inorganic sulfate concentration, a precursor to 3-phospho adenosine
5’-phosphosulfate (PAPS), and these options are currently being
investigated. However, no differences in inorganic sulfate levels were noted in
CF patients, despite a higher CLf,AS 14 ; therefore, increased
inorganic sulfate levels are unlikely to be the cause of higher CLf,AS in the mice.
Transport of the conjugates out of the cell may also be
rate-limiting, which would result in an increase in levels of intracellular
conjugate and possibly result in product inhibition25-27. Analogous to rats
and humans, CF mice probably excrete AG from hepatocytes via either oatp
(organic anion transporting polypeptide), or mrp1 (multidrug resistance
associated protein-1) or some as yet unidentified transporter involved in the
transport of anions. As with AG, AS is very polar and is a strong acid;
therefore, it may also depend on membrane transporters to be excreted from
hepatocytes. Previous studies in fetal sheep indicate that AG and AS are not
passively transported across the placenta28 ; therefore, it is likely that their removal from hepatocytes is facilitated.
Increased clearance of drugs like APAP in CF could arise from
an increased expression of transporters, resulting in either increased uptake or
efflux of the drug. There is precedence for this statement in that coordinate
regulation between expression of cftr and mdr1 has been reported to occur across
several species29-31. A recent study by Trezise et al, 199729 suggests
that expression of transporters like mdr1 (multidrug resistance) may be
coordinately regulated with ctfr expression. An inverse relationship between
cftr and mdr1 expression in the CF mouse with heterozygous mice showing
an intermediate level of expression and homozygous CF competent mice (+/+)
having lowest levels of mdr has been demonstrated.
ICG is a high extraction ratio probe in humans, which is
exclusively cleared by the liver. ICG is efficiently excreted in bile without
the need for metabolism, because of its large molecular weight and inherent
charge. However, it appears that in the CF-knockout mice, ICG is only a moderate
extraction ratio drug (E = 0.6). This conclusion is based on a published value
for hepatic blood flow in the mouse of 86 mL/min per kg32. Because both hepatic blood flow and bile acid uptake have been found to be normal in patients
with CF33 , ICG should provide a more direct measure of whether specific hepatic transporters are altered in CF. It is possible that the genetic defect
in CF that alters transmembrane regulation of ion flux (ie, cystic fibrosis
transmembrane regulator [cftr] protein) may also increase either the cellular
uptake of ICG or its eventual secretion into the bile. Following administration
of ICG, homozygous CF-knockout mice had results qualitatively similar to CF
patients, with a trend toward a decreased Cmax and an increased V relative to heterozygous mice. However, in contrast to humans, no difference in
CL of ICG was observed in the cftr mice relative to heterozygous controls
(Table 3 ). It is probable that the rate-limiting
step in the elimination of ICG, either uptake or efflux, may be different
between species.
Increased volume of distribution has been reported for a
large number of compounds in CF (eg, antipyrine, lorazepam, and ICG)2. It has
been suggested that in CF patients, chronic reduction in systemic arterial
oxygen saturation, which is observed with increasing severity of pulmonary
disease, is often associated with increases in both erythrocyte count and plasma
volume. These alterations result in an increase in body water/body mass ratio,
effectively increasing the available distribution space for drugs that partition
to both intravascular and extravascular spaces2. It should be noted that this difference in V in female CF mice is not attributable to altered blood-to-plasma
ratio of ICG. Blood-to-plasma ratios for ICG were not different between
homozygous and heterozygous female mice.
Conclusion
In summary, this study shows that, similar to CF patients,
CLf and CLR of AS is increased in homozygous CF male mice
relative to heterozygous (+/-) controls. A trend toward an increased CLf and CLR of AG was noted, with no significant differences. This
trend may be attributed to the fact that a diverse group of mice (ages 20 to 48
weeks) were used in this study because of limited availability of these mice.
Also, (+/+) mice were not used as controls in these studies. The studies by
Trezise et al in 199729 indicate that if the increased clearance comes from expression levels of a transporter, then (+/+) mice would serve as better
controls. Results with ICG indicate that homozygous CF mice demonstrate a trend
toward a decreased Cmax and an increased V relative to heterozygous mice. However, in contrast to results from CF patients, no difference in CL of
ICG is noted in CF mice. The use of (+/+) mice as controls in future studies may
increase the ability to discriminate the effects of altered cftr on drug
disposition.
We conclude that the CF-knockout mouse model has potential
for being employed as an animal model for predicting altered clearance in CF
patients. Future studies using (+/+) mice as controls and a wider range of drugs
are ongoing.
Acknowledgements
This research was supported in part by the School of Pharmacy
Foundation, NIH GM41828, and the Cystic Fibrosis Center, University of North
Carolina-Chapel Hill. A preliminary report of these findings was presented at
the 1998 AAPS Annual Meeting, AAPS PharmSci Supplement 1:S675.
References
1.
Welsh MJ, Smith AE. Cystic fibrosis. Scientific American. 1995;273:52-59.
[PUBMED]
2.
Kearns GL, Mallory GB, Crom WR, Evans WE. Enhanced hepatic
drug clearance in patients with cystic fibrosis. Pediatr Pharmacol Ther. 1990;117:972-979.
[PUBMED]
3.
Kearns GL. Hepatic drug metabolism in cystic fibrosis:
recent developments and future directions. Ann Pharmacother. 1993;27:74-79.
[PUBMED]
4.
Kearns GL, Crom WR, Karlson KH, Mallory GB, Evans WE.
Hepatic drug clearance in patients with mild cystic fibrosis. Clin Pharmcol Ther. 1996;59:529-540.
[PUBMED]
5.
Hutabarat RM, Unadkat JD, Kushmerick P, Aitken ML, Slattery
JT, Smith A. Disposition of drugs in cystic fibrosis. III. Acetaminophen.Clin Pharmacol Ther. 1991;50:695-701.
[PUBMED]
6.
Cressman VL, Hicks EM, Funkhouser WK, Backlund DC, Koller
BH. The relationship of chronic mucin secretion to airway disease in normal and
cftr-deficient mice. Am J Resp Cell Mol Biol. 1998;19:853-866.
[PUBMED]
7.
Snouwaert JN, Brigman KK, Latour et al. An animal model for
cystic fibrosis made by gene targeting. Science. 1992;257:1083-1088.
[PUBMED]
8.
Miller DA, Dykes DD, Polesky HF. A simple salting out
procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
[PUBMED]
9.
Wang LH, Rudolph AM, Benet LZ. Pharmacokinetic studies of
the disposition of acetaminophen in the sheep maternal-placental-fetal unit. J Pharmacol Exp Ther. 1986;238:198-205.
[PUBMED]
10.
Heintz R, Svensson CK, Stoeckel K, Powers GJ, Lalka D.
Indocyanine green: pharmacokinetics in the rabbit and relevant studies of its
stability and purity. J Pharm Sci. 1986;75:398-402.
[PUBMED]
11.
Ott P, Keiding S, Bass L. Plasma elimination of
indocyanine green in the intact pig after bolus injection and during constant
infusion: comparison of spectrophotometry and high-pressure liquid
chromatography for concentration analysis. Hepatology. 1993;6:1504-1515.
[PUBMED]
12.
Falls JG, Blake BL, Cao Y, Levi PE, Hodgson, E. Gender
differences in hepatic expression of flavin-containing monooxygenase isoforms
(FMO1, FMO3, and FM05) in mice. J Biochem Tox. 1995;10:171-177.
[PUBMED]
13.
Rao UN, Aravindakshan M, Satyanarayan V, Chauhan PS.
Genotype-and gender-dependent hepatic alcohol dehydrogenase (ADH) activity in
developing mice. Alcohol. 1997;14:527-531.
[PUBMED]
14.
Kane RE, Tector J, Brems JJ, Li AP, Kaminski DL. Sulfation
and glucuronidation of acetaminophen by cultured hepatocytes replicating in vivo
metabolism. ASAIO Transactions. 1990;36:607-610.
[PUBMED]
15.
Surh YJ, Liem A, Miller EC, Miller JA. Age-and sex-related
differences in activation of the carcinogen
7-hydroxymethyl-12-methylbenz[a]anthracene to an electrophilic sulfuric acid
|